# A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

Study · id `cardio:ct-nct02533453` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02533453](<https://clinicaltrials.gov/study/NCT02533453>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02533453

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02533453. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01-28 (actual); primary completion 2016-12-07 (actual). Results posted on 2019-05-31.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Started: 2016-01-28 (actual) (ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Primary completion: 2016-12-07 (actual) (ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Completion: 2016-12-07 (actual) (ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Results first posted: 2019-05-31 (ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02533453, source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02533453-2019-05-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
- Acronym: Bydureon
- Condition: Type 2 Diabetes Mellitus
- Intervention (Biological): Bydureon
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 3e23d348d5d03d132e709964a83df05f69e342cf39335e56cf3744c562ac33f4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
